Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 9/20 | 0.67 |
| ▸ | LNPEP | Q9UIQ6 | 9/20 | 0.67 |
| ▸ | ERAP1 | Q9NZ08 | 7/20 | 0.67 |
| ▸ | NPY4R | P50391 | 2/20 | 0.60 |
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | IL1RN | P18510 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.54 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498151 | 0.89 | BIRC2 (0.62) | ERAP2LNPEPERAP1TSHROPRM1 | |
| SCHEMBL29468059 | 0.88 | MME (0.60) | ERAP2LNPEPERAP1NPY4RNPY1R | |
| SCHEMBL27824405 | 0.87 | ERAP2 (0.64) | ERAP2LNPEPERAP1NPY4RNPY1R | |
| SCHEMBL27824408 | 0.87 | ERAP2 (0.64) | ERAP2LNPEPERAP1NPY4RNPY1R | |
| SCHEMBL12047661 | 0.85 | ERAP2 (0.61) | ERAP2LNPEPERAP1NPY4RNPY1R | |
| SCHEMBL24345964 | 0.84 | BIRC2 (0.66) | BIRC2 | |
| Hydrochloric Acid SCHEMBL7698566 | 0.84 | TSHR (0.58) | ERAP2LNPEPERAP1NPY4RNPY1R | |
| SCHEMBL14509566 | 0.84 | TSHR (0.58) | ERAP2LNPEPERAP1NPY4RNPY1R | |
| SCHEMBL30759435 | 0.83 | ERAP2 (0.53) | ERAP2LNPEPERAP1NPY4RNPY1R | |
| SCHEMBL29656807 | 0.83 | BIRC2 (0.64) | ERAP2LNPEPERAP1IL1RNTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | ERAP2 3495/4885LNPEP 967/4885ERAP1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.